Margin expansion crucial for Cipla's stock

Continued efforts on growth in global markets is positive and will accrue benefits over time

Ujjval Jauhari  |  New Delhi 

Cipla continues to strengthen its global footprint. Wednesday's acquisition of Anmarate (Pty) Ltd in South Africa and Cipla USA entering into a collaboration with MEDRx a few days ago are steps in this direction. Such moves will help Cipla report healthy top-line growth, but analysts say improvement in profitability is equally crucial. The acquisition of Anmarate will add to Cipla's strengths in South Africa, which contributes 13 per cent to its revenues. The US collaboration is to take further the development and commercialisation of MRX-4TZT. To bolster the US generic ...

TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH

Key stories on business-standard.com are available to premium subscribers only.

LOGIN

EMAIL / USER NAME
PASSWORD
REMEMBER ME Forgot password?
LOGIN

Not a member yet ? Resister Now

Connect using any below

  • Don't lose the opportunity of saving $26.77 per month
  • Don't lose the opportunity of saving $26.77 per month
Total Amount
Rs. 0.00
To proceed, kindly select a subscription package

WHAT YOU GET

On Business Standard Digital

  • Access your subscription from anywhere. Be it your computer, tablet or smartphone using a browser or the App, Your Choice.
  • Access to exclusive content, features, opinions and comment, hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get all the news upates at the end of each day through E-Mail.
  • Pick the industry that you want to track. And get a daily news letter specific to that industry. Cut out the clutter.
  • And stay on top of your investments. Track stock prices in your portfolio
  • Access 18 years of archival data

On Digital

  • Seamless access to WSJ.com with your Business Standard digital account.
  • Experience the best of the Journal's reporting, video and interactive features.
  • Read about the people and events shaping business, finance, technology, politics, technology and culture.
  • Stay informed with newsletters - an easy way to get WSJ content straight to your inbox - making life easier on your busiest days.
  • More business executives read the Journal globally than any other publication.
*Note :
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital

Margin expansion crucial for Cipla's stock

Continued efforts on growth in global markets is positive and will accrue benefits over time

Cipla continues to strengthen its global footprint. Wednesday's acquisition of Anmarate (Pty) Ltd in South Africa, and Cipla USA entering into a collaboration with MEDRx a few days ago, are a step in this direction. Such moves will help Cipla report healthy topline growth, but analysts say improvement in profitability is equally crucial.The acquisition of Anmarate, which develops and manufactures medicines and medical devices, will add to Cipla's strengths in South Africa, which already contributes about 13 per cent to its revenues. The US collaboration is to take further the development and commercialisation of MRX-4TZT, a tizanidine1 patch for the management of spasticity. This will enhance Cipla's presence in branded specialty space. To bolster the US generic business, Cipla has already completed two acquisitions last year. It is also on course for achieving full year guidance of 20-25 ANDAs (abbreviated new drug applications) having already filed 21 ANDAs during first nine months . Cipla continues to strengthen its global footprint. Wednesday's acquisition of Anmarate (Pty) Ltd in South Africa and Cipla USA entering into a collaboration with MEDRx a few days ago are steps in this direction. Such moves will help Cipla report healthy top-line growth, but analysts say improvement in profitability is equally crucial. The acquisition of Anmarate will add to Cipla's strengths in South Africa, which contributes 13 per cent to its revenues. The US collaboration is to take further the development and commercialisation of MRX-4TZT. To bolster the US generic ... image
Business Standard
177 22